Research Center: Clever Medical Research LLC
Location: 1150 NW 72nd Ave, Suite 500, Miami, FL 33126
Lead Researcher: Dr. Mojgan Hosseinipour, DO, FAAD
IRB: This study has been reviewed and approved by the WCG Institutional Review Board
About the Study
Living with atopic dermatitis can be challenging, but you don’t have to face it alone. This Clever Medical Research LLC study offers an opportunity to explore new possibilities. By participating, you can help researchers learn more about AD, and potentially find new ways to manage it. Join this research journey and make a difference in eczema treatment today!
Why Participate?
- Participants will receive a new potential treatment for AD at no cost.
- Participants will be compensated for participating in this study. Compensation will only be provided to eligible participants who complete the study.
- Participants may experience improvements in symptoms related to atopic dermatitis.
- Participants will be contributing valuable information that may benefit those with AD in the future.
- Participants will be helping to advance medical research.
Your Rights
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
- Any information that you provide will be kept strictly confidential, except as required by law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 18+ who are diagnosed with Atopic Dermatitis (Eczema)
- Must have AD that is red, itchy, and crusty
- Must have AD in at least 10 percent of the body
- Must not currently be pregnant or breastfeeding
- Must not have a skin co-morbidity that would adversely affect the ability to undertake AD assessments (eg, psoriasis, tinea corporis, lupus erythematosus)
- Must not have a history of hypersensitivity or allergy to any medications
- Must not have a history of alcohol or substance abuse in the past 2 years
- Must be able to attend 24 study visits at the research site over approximately 5 weeks
More Study Details
The study team will explain the research in its entirety but some details are:
- Participants must comply with study visits and procedures, including a screening period of 2 to 4 weeks, a treatment period of 24 weeks, and a post-treatment safety follow-up period of 16 weeks.
- Participants will receive either amlitelimab or a placebo via injections. Over the treatment period, participants will receive 7 injections: 2 on the first day and 1 every 4 weeks over 5 visits.
- Participants will need to apply moisturizers daily and manage their current topical AD medication as per the study doctor’s instructions.
About the Research Center
Clever Medical Research LLC
At Clever Medical Research, we believe in the power of research to transform lives. Through our unwavering dedication to scientific inquiry and patient advocacy, we strive to make meaningful contributions to the advancement of medicine and ultimately, to the well-being of humanity.
Please note:
Due to the COVID-19 pandemic, the researchers would like to assure the participants that ensuring their and the study staff’s safety is of utmost importance.